TGF-beta2 antisense oligonucleotide TASO-001
Term · Oncology and biomedicine · MLC-T-ONC-017105
A transforming growth factor (TGF)-beta2 specific antisense oligodeoxynucleotide (ASO), with potential antineoplastic activity. Upon administration, TGF-beta2 ASO TASO-001 binds to TGF-beta2 mRNA causing inhibition of protein translation. This decreases TGF-beta2 levels, which may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine overexpressed in various malignancies, plays an important role in promoting the growth, progression, and migration of tumor cells.
| Identifier | MLC-T-ONC-017105 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | TGF-beta2-targeting antisense oligonucleotide TASO-001; TGF-beta2 ASO TASO-001 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017105",
"term": "TGF-beta2 antisense oligonucleotide TASO-001",
"field": "Oncology and biomedicine",
"definition": "A transforming growth factor (TGF)-beta2 specific antisense oligodeoxynucleotide (ASO), with potential antineoplastic activity. Upon administration, TGF-beta2 ASO TASO-001 binds to TGF-beta2 mRNA causing inhibition of protein translation. This decreases TGF-beta2 levels, which may result in the inhibition of tumor cell growth and migration, and tumor angiogenesis. TGF-beta2, a cytokine overexpressed in various malignancies, plays an important role in promoting the growth, progression, and migration of tumor cells.",
"synonyms": [
"TGF-beta2-targeting antisense oligonucleotide TASO-001",
"TGF-beta2 ASO TASO-001"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/tgf-beta2-antisense-oligonucleotide-taso-001/"
}
Record 16,223 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.